培米替尼价格一览

Pemetinib is a targeted drug used to treat cholangiocarcinoma, especially for patients with FGFR2 gene fusion or rearrangement. This article will conduct a detailed analysis of pemetinib’s original drug and generic drug prices, domestic marketing status, and medical insurance reimbursement status to help patients better understand the economy and accessibility of the drug.

Pemetinib original drug and generic drug prices

The original drug has been launched in China, and its price varies depending on the specifications. The price is for reference only. The price of generic drugs is relatively low, but the specific price varies by brand and region.

Original drug price

The original drug of pemetinib is produced by Incyte Biosciences Distribution B.V., and the price is relatively high. The price of a box of 9mg*14 pills is about US$5,781, and the price of a box of 4.5mg*14 pills is about US$3,400. This price reflects the R&D costs and market positioning of pemetinib as an innovative drug.

Price of generic drugs

The price of generic drugs is relatively low, but the specific price varies depending on the brand and region. For example, the specification of Lucius's generic pemetinib in Laos is 4.5mg*14 tablets, and the price of a box is about US$60. Patients should pay attention to the quality and efficacy of the drug when choosing generic drugs.

There is a large price difference between the original drug and generic drug of pemetinib, and patients can choose according to their own economic situation and treatment needs.

Pemetinib’s domestic launch situation

The original drug of pemetinib has been launched in China, and Innovent Biologics (Suzhou) Co., Ltd. is responsible for subpackaging and sales. The drug was conditionally approved for marketing on March 29, 2022, for the treatment of patients with cholangiocarcinoma with FGFR2 gene fusion or rearrangement.

Time to market

The original drug of pemetinib was conditionally approved for marketing on March 29, 2022, marking the drug’s official entry into the Chinese market. This time to market provides a new treatment option for domestic patients with cholangiocarcinoma.

Sales channels

The original drug of pemetinib is packaged and sold by Innovent Biologics (Suzhou) Co., Ltd. Patients can purchase the drug through designated hospitals or pharmacies.

The medical insurance reimbursement situation of pemetinib

The medical insurance reimbursement situation of pemetinib varies according to different regions and policies. Currently, the drug has not been included in the national medical insurance catalog, but the medical insurance policies in some regions may provide certain reimbursement support.

National Reimbursement Directory

Pemetinib has not yet been included in the National Reimbursement Directory, which means that patients need to purchase the drug at their own expense. As the clinical data of the drug accumulates and market demand increases, it is expected to be included in the National Reimbursement Directory in the future.

Local medical insurance policies

The medical insurance policies in some areas may provide certain reimbursement support. Some local governments or medical institutions may provide reimbursement support to patients through special approval procedures. Patients can consult the local medical insurance department for specific conditions.

The medical insurance reimbursement situation of pemetinib varies according to different regions and policies. Patients can consult the local medical insurance department for specific reimbursement policies.